


<b>Name</b>	Dr Felix Chua	
<b>Country</b>	United Kingdom	
<b>Organization</b>	Royal Brompton Hospital and National Heart & Lung Institute, Imperial College London	
<b>Current Position</b>	Consultant Respiratory Physician and Hon. Senior Lecturer	

### Educational Background

B.Sc (Hons.)	Royal Free Hospital School of Medicine Intercalated Program (1992)
MB.BS	Royal Free Hospital School of Medicine (1995)
PhD	University College London (2006)
FRCP	Royal College of Physicians (2012)

### Professional Experiences

Pulmonologist/Consultant Respiratory Physician involved in managing interstitial lung disease since 2008, including developing a new ILD clinical service and setting up a joint Rheumatology-ILD clinic at St George's Hospital, London before moving to the Royal Brompton Hospital in 2014.

I am presently a senior ILD physician at RBH and have an honorary senior lectureship with the National Heart and Lung Institute, Imperial College London. I am also a member of the European Respiratory Society task force for developing guidance on transition care for paediatric ILD patients. Since 2022, I have assumed the role of Clinical Lead in rare diseases for the Southeast England Genomics Laboratory Hub.

### Professional Organizations

European Respiratory Society  
British Thoracic Society  
British Association for Lung Research

### Main Scientific Publications

#### Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?

Chua F, Low S, Chai GT, Inoue Y, Ong V, Wongkarnjana A, Kawkitinarong K, Song JW, Hamid ZA, Aziz AA, Campomanes M, Maher TM, Molyneaux PL, Syakirin S.

*Lancet Respir Med* 2023 Apr 4:S2213-2600(23)00125-X. doi: 10.1016/S2213-2600(23)00125-X

#### Combination of Bronchoalveolar Lavage and CT Differentiates Progressive and Non-Progressive Fibrotic Lung Diseases.

Barnett JL, Maher TM, Quint JK, Adamson A, Wu Z, Smith DJF, Rawal B, Nair A, Walsh SL, Desai SR, George PM, Kokosi M, Jenkins G, Kouranos V, Renzoni EA, Rice A, Nicholson AG, Chua F, Wells AU, Molyneaux PL, Devaraj A. *Am J Respir Crit Care Med*. 2023 Sep 6. doi: 10.1164/rccm.202305-0796OC

**Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.**

Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL, on behalf of the RECITAL Investigators. *Lancet Resp Med* 2023; 11: 45-54. [https://doi.org/10.1016/S2213-2600\(22\)00359-9](https://doi.org/10.1016/S2213-2600(22)00359-9).

Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases. Stock CJW, Bray WG, Kouranos V, Jacob J, Kokosi M, George PM, Chua F, Wells AU, Sestini P, Renzoni EA. *Respirology*. 2023 Oct 1. doi: 10.1111/resp.14609

**Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study.**

Raman L, Stewart I, Barratt SL, Chua F, Chaudhuri N, Crawshaw A, Gibbons M, Hogben C, Hoyles R, Kouranos V, Martinovic J, Mulholland S, Myall KJ, Naqvi M, Renzoni EA, Saunders P, Steward M, Suresh D, Thillai M, Wells AU, West A, Mitchell JA, George PM. *Eur Resp J Open Res*. 2023 Mar 20;9(2):00423-2022. doi: 10.1183/23120541.00423-2022.

**Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.**

Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, Vo V, Renzoni EA, Wells AU, Garcia CK, Chua F, Newton CA, Molyneaux PL, Oldham JM. *Am J Respir Crit Care Med*. 2022. doi: 10.1164/rccm.202201-0124OC.

**Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study.**

Dawes TJW, McCabe C, Dimopoulos K, Stewart I, Bax S, Harries C, Samayake CB, Kempny A, Molyneaux PL, Seitler S, Semple T, George P, Kouranos V, Chua F, Renzoni EA, Kokosi M, Jenkins G, Wells AU, Wort SJ, Price LC. *Respirology*. 2022. doi: 10.1111/resp.14378.

**Lung cancer screening provides an opportunity for early diagnosis and treatment of interstitial lung disease.**

Hewitt RJ, Bartlett EC, Ganatra R, Butt H, Kouranos V, Chua F, Kokosi M, Molyneaux PL, Desai SR, Wells AU, Jenkins RG, Renzoni EA, Kemp SV, Devaraj A, George PM. *Thorax*. 2022. doi: 10.1136/thorax-2022-219068. Epub 2022 Aug 8.

**Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis.**

Macaluso C, Boccabella C, Kokosi M, Sivarasan N, Kouranos V, George PM, Margaritopoulos G, Molyneaux PL, Chua F, Maher TM, Jenkins GR, Nicholson AG, Desai SR, Devaraj A, Wells AU, Renzoni EA, Stock CJW. *Respirology* 2022. doi: 10.1111/resp.14204.

**CYFRA 21-1 Predicts Progression in IPF: A Prospective Longitudinal Analysis of the PROFILE Cohort.**

Molyneaux PL, Fahy WA, Byrne AJ, Braybrooke R, Saunders P, Toshner R, Albers G, Chua F, Renzoni EA, Wells AU, Karkera Y, Oballa E, Saini G, Nicholson AG, Jenkins G, Maher TM.

*Am J Respir Crit Care Med* 2022. doi: 10.1164/rccm.202107-1769OC. Online ahead of print. PMID: 35363592

#### **Lung function trajectory in progressive fibrosing interstitial lung disease.**

Oldham JM, Lee CT, Wu Z, Bowman WS, Vu Pugashetti J, Dao N, Tonkin J, Seede H, Echt G, Adegunsoye A, Chua F, Maher TM, Garcia CK, Streck ME, Newton CA, Molyneaux PL.

*Eur Respir J* 2021: 2101396. doi: 10.1183/13993003.01396-2021.

#### **Delays in idiopathic pulmonary fibrosis diagnosis and treatment: Time for change.**

Jee AS, Chua F.

*Respirology* 2022 Jan;27(1):10-11. doi: 10.1111/resp.14189. Epub 2021 Nov 30.

#### **Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score.**

Felix Chua,<sup>2\*</sup> Rama Vancheeswaran,<sup>1\*</sup> Adrian Draper,<sup>3\*</sup> Tejal Vaghela,<sup>4</sup> Matthew Knight,<sup>1</sup> Rahul Mogal,<sup>1</sup> Jaswinder Singh,<sup>1</sup> Lisa G Spencer,<sup>5</sup> Erica Thwaite,<sup>6</sup> Harry Mitchell,<sup>1</sup> Sam Calmonson,<sup>1</sup> Noor Mahdi,<sup>1</sup> Shershah Assadullah,<sup>1</sup> Matthew Leung,<sup>1</sup> Aisling O'Neill,<sup>1</sup> Chayya Popat,<sup>1</sup> Radhika Kumar,<sup>1</sup> Thomas J Humphries,<sup>5</sup> Rebecca Talbutt,<sup>5</sup> Sarika Raghunath,<sup>5</sup> Philip L Molyneaux,<sup>2</sup> Miriam Schechter,<sup>4</sup> Jeremy Lowe,<sup>4</sup> Andrew Barlow<sup>1</sup>

*Thorax* 2021. Early e-pub thoraxjnl-2020-216425. doi: 10.1136/thoraxjnl-2020-216425.

#### **Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.**

Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, Babu S, Barber CM, Barratt S, Bendstrup E, Bianchi S, Villegas DC, Chaudhuri N, Chua F, Coker R, Chang W, Crawshaw A, Crowley LE, Dosanjh D, Fiddler CA, Forrest IA, George PM, Gibbons MA, et al. ISARIC4C Investigators. *Am J Respir Crit Care Med*. 2020 Dec: 1656-65. doi: 10.1164/rccm.202007-2794OC.

#### **BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study.**

Molyneaux PL, Smith JJ, Saunders P, Chua F, Wells AU, Renzoni EA, Nicholson AG, Fahy WA, Jenkins RG, Maher TM. *Am J Respir Crit Care Med*. 2021 Jan 1;203(1):136-139. doi: 10.1164/rccm.202004-1138LE.

#### **The respiratory microbiome in chronic hypersensitivity pneumonitis is distinct from that of idiopathic pulmonary fibrosis.**

Invernizzi R, Wu BG, Barnett J, Ghai P, Kingston S, Hewitt RJ, Feary J, Li Y, Chua F, Wu Z, Wells AU, Renzoni EA, Nicholson AG, Rice A, Devaraj A, Segal LN, Byrne AJ, Maher TM, Lloyd CM, Molyneaux PL.

*Am J Respir Crit Care Med* 2020. DOI: 10.1164/rccm.202002-0460OC.

#### **The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions.**

The logo for KATRD features a stylized flame or drop shape on the left, composed of overlapping blue, orange, and green elements. To the right of this graphic, the letters 'KATRD' are stacked vertically in a bold, sans-serif font, with the 'K' and 'A' in blue, 'T' in orange, and 'R' and 'D' in green.

**KATRD**

The 136th Congress of the Korean Academy of Tuberculosis  
and Respiratory Diseases

## International Conference 2023

November 8 (Wed) - 10 (Fri), 2023 / Lotte Hotel World, Seoul, Korea

[www.katrdic.org](http://www.katrdic.org)

---

**Chua F, Armstrong-James D, Desai SR, Barnett J, Kouranos V, Kon OM, José R, Vancheeswaran R, Loebinger MR, Wong J, Cutino-Moguel MT, Morgan C, Ledot S, Lams B, Yip WH, Li L, Lee YC, Draper A, Kho SS, Renzoni E, Ward K, Periselneris J, Grubnic S, Lipman M, Wells AU, Devaraj A.**

*Lancet Resp Med* 2020; 8: 438-440. DOI: 10.1016/S2213-2600(20)30132-6.

---